These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 25527197

  • 1. TRKing down an old oncogene in a new era of targeted therapy.
    Vaishnavi A, Le AT, Doebele RC.
    Cancer Discov; 2015 Jan; 5(1):25-34. PubMed ID: 25527197
    [Abstract] [Full Text] [Related]

  • 2. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA.
    Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
    [Abstract] [Full Text] [Related]

  • 3. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ, Zehir A, Sireci AN, Aisner DL.
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [Abstract] [Full Text] [Related]

  • 4. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.
    Kheder ES, Hong DS.
    Clin Cancer Res; 2018 Dec 01; 24(23):5807-5814. PubMed ID: 29986850
    [Abstract] [Full Text] [Related]

  • 5. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 01; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 6. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF, Demetri GD.
    Future Oncol; 2020 Mar 01; 16(9):417-425. PubMed ID: 32129093
    [Abstract] [Full Text] [Related]

  • 7. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
    Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW.
    J Clin Oncol; 2019 Feb 20; 37(6):513-524. PubMed ID: 30592640
    [Abstract] [Full Text] [Related]

  • 8. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 20; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 9. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS, Lassen U.
    Drugs; 2021 Mar 20; 81(4):445-452. PubMed ID: 33400240
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K, Pellat A, Cohen R, Svrcek M, Penault-Llorca F, André T.
    Bull Cancer; 2020 Apr 20; 107(4):447-457. PubMed ID: 32067719
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.
    J Natl Cancer Inst; 2016 Jan 20; 108(1):. PubMed ID: 26563355
    [Abstract] [Full Text] [Related]

  • 17. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J.
    Oncotarget; 2016 Feb 16; 7(7):8399-412. PubMed ID: 26716414
    [Abstract] [Full Text] [Related]

  • 18. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
    Farina AR, Cappabianca L, Ruggeri P, Gneo L, Pellegrini C, Fargnoli MC, Mackay AR.
    J Exp Clin Cancer Res; 2018 Jun 18; 37(1):119. PubMed ID: 29914559
    [Abstract] [Full Text] [Related]

  • 19. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
    Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A, Scaltriti M, Drilon A, Iasonos A, Taylor BS, Hyman DM.
    Clin Cancer Res; 2020 Apr 01; 26(7):1624-1632. PubMed ID: 31871300
    [Abstract] [Full Text] [Related]

  • 20. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS, Sigal D.
    Curr Oncol Rep; 2019 Feb 04; 21(2):14. PubMed ID: 30715603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.